These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9400534)

  • 1. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee of the UKHCDO. United Kingdom Haemophilia Centre Directors' Organisation.
    Ludlam CA
    Lancet; 1997 Dec; 350(9092):1704. PubMed ID: 9400534
    [No Abstract]   [Full Text] [Related]  

  • 2. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee UK Haemophilia Directors' Organisation.
    Ludlam CA
    Lancet; 1998 Apr; 351(9111):1289-90. PubMed ID: 9643779
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience.
    Dolan G
    Haemophilia; 2006 Mar; 12 Suppl 1():16-20; discussion 26-8. PubMed ID: 16445813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemophilia patient had variant CJD agent in spleen.
    Eaton L
    BMJ; 2009 Feb; 338():b705. PubMed ID: 19224963
    [No Abstract]   [Full Text] [Related]  

  • 5. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia.
    Baxter T; Black D; Birks D
    Lancet; 1998 Feb; 351(9102):600-1. PubMed ID: 9492811
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and organisational aspects of haemophilia care: the patients' view.
    Calizzani G; Arcieri R
    Blood Transfus; 2012 Jan; 10(1):110-1. PubMed ID: 22044947
    [No Abstract]   [Full Text] [Related]  

  • 7. Factor VIII and transmissible spongiform encephalopathy: the case for safety.
    Cervenakova L; Brown P; Hammond DJ; Lee CA; Saenko EL
    Haemophilia; 2002 Mar; 8(2):63-75. PubMed ID: 11952840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Creutzfeldt-Jakob disease and haemophilia: prospect at the new millennium.
    Liras A
    Haemophilia; 2000 Nov; 6(6):716-8. PubMed ID: 11122406
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk reduction strategies for variant Creutzfeldt-Jakob disease transmission by UK plasma products and their impact on patients with inherited bleeding disorders.
    Millar CM; Connor N; Dolan G; Lee CA; Makris M; Wilde J; Winter M; Ironside JW; Gill N; Hill FG
    Haemophilia; 2010 Mar; 16(2):305-15. PubMed ID: 20487442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor VIII may not abolish risk of new variant CJD from factor VIII.
    Betts JP
    BMJ; 1998 May; 316(7141):1385. PubMed ID: 9564003
    [No Abstract]   [Full Text] [Related]  

  • 11. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology.
    Keeling D; Tait C; Makris M
    Haemophilia; 2008 Jul; 14(4):671-84. PubMed ID: 18422612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Batch recall of French plasma-derived products due to variant Creutzfeldt-Jakob disease risk: the psychological impact on haemophilic patients, changes in their therapeutic demands and behaviour and ethical considerations.
    Aouba A; Harroche A; Frenzel L; Torchet MF; Rothschild C; François I; Mamzer-Bruneel MF
    Haemophilia; 2015 Jan; 21(1):27-33. PubMed ID: 25545300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations for the treatment of factor VIII inhibitors: from the UK Haemophilia Centre Directors' Organisation Inhibitor Working Party.
    Hay CR; Colvin BT; Ludlam CA; Hill FG; Preston FE
    Blood Coagul Fibrinolysis; 1996 Mar; 7(2):134-8. PubMed ID: 8735802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Creutzfeldt-Jakob disease and haemophilia: assessment of risk.
    Evatt B
    Haemophilia; 2000 Jul; 6 Suppl 1():94-9. PubMed ID: 10982274
    [No Abstract]   [Full Text] [Related]  

  • 15. The 2000 United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) inhibitor guidelines.
    Hay CR;
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():19-21. PubMed ID: 12214141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second Workshop of the European Paediatric Network for Haemophilia Management, 17-19 September 1998 in Vitznau/Switzerland.
    Ljung R
    Haemophilia; 1999 Jul; 5(4):286-91. PubMed ID: 10950622
    [No Abstract]   [Full Text] [Related]  

  • 17. Who should receive recombinant factor VIII?
    Giangrande PL
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S25-7. PubMed ID: 9351533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variant Creutzfeldt-Jakob disease and prions in the blood supply.
    Rohwer RG; Drohan W
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):84, 87, 131. PubMed ID: 16163166
    [No Abstract]   [Full Text] [Related]  

  • 19. Mortality and haemophilia.
    Goedert JJ
    Lancet; 1995 Nov; 346(8987):1425-6. PubMed ID: 7475837
    [No Abstract]   [Full Text] [Related]  

  • 20. Creutzfeld-Jacob disease and blood product recalls.
    Colvin R; Dubin C; Haas G
    Common Factor; 1994 Apr; (no 10):23. PubMed ID: 11362357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.